Growth & GH-AxisBlend / Stack

CJC-1295 + Ipamorelin Blend

Combination product: GHRH analog (CJC-1295) + GHRP/ghrelin-receptor agonist (ipamorelin)

A research-supplier blend combining the GHRH analog CJC-1295 with the GH-secretagogue Ipamorelin, often paired in growth-axis research.

Also referenced as: CJC-1295/Ipamorelin blend

Blend

Overview

This is not a single molecule but a formulated blend combining CJC-1295 (a GHRH analog) with ipamorelin (a selective ghrelin-receptor GH secretagogue). Blends are commonly prepared in research/compounding contexts to combine two complementary GH-stimulating mechanisms.

At a glance

ClassCombination product: GHRH analog (CJC-1295) + GHRP/ghrelin-receptor agonist (ipamorelin)

CategoryGrowth & GH-Axis

Typical formLyophilized powder

AliasesCJC-1295/Ipamorelin blend

Use designationResearch / in-vitro only

Regulatory statusThis CJC-1295 + ipamorelin blend is not approved by the FDA or EMA; both components are research-only, and the blend is used in research/compounding contexts only, not as an approved medicine.

What CJC-1295 + Ipamorelin Blend does

The CJC-1295 / ipamorelin blend combines two secretagogues that act on separate, complementary arms of the GH-release system, which is precisely why they are studied together. CJC-1295 (typically the no-DAC / Mod GRF 1-29 form) is a GHRH analog: it binds pituitary GHRH receptors and increases the AMOUNT of growth hormone released in a pulse. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist: it primes the somatotrophs, mimics ghrelin's secretagogue signal, and suppresses somatostatin — the brake on GH release. Because one raises pulse amplitude while the other disinhibits and sensitizes the pituitary, co-administration produces a GH pulse in research models that is larger than the sum of either peptide given alone — the classic synergy behind GHRH-plus-GHS pairings.

The pairing is also chosen for its cleanliness. Ipamorelin is the most selective of the GHS-R agonists, so it adds GH-releasing power without the cortisol, ACTH, and prolactin bumps or the strong appetite drive seen with GHRP-6. The net effect studied is a robust but relatively physiologic GH pulse followed by a downstream rise in IGF-1, with the two short-acting peptides preserving pulsatility rather than clamping GH continuously high.

This is a combination of two research compounds; evidence rests on the individual peptides' preclinical and early-pharmacology data plus the well-documented GHRH+GHS synergy, not on trials of the specific blend.

Effects reported in research

Generated a synergistically larger GH pulse than either component alone by combining GHRH-receptor and GHS-R1a mechanisms (preclinical basis for the pairing).
CJC-1295 component increased GH released per pulse (amplitude) via GHRH-receptor agonism.
Ipamorelin component primed somatotrophs and suppressed somatostatin, disinhibiting release.
Raised downstream IGF-1 following the amplified GH pulse.
Kept the pulse relatively clean — ipamorelin's selectivity avoids the cortisol/ACTH/prolactin rises of less selective GHRPs (animal data).
Preserved pulsatile GH secretion because both components are short-acting (no-DAC form).
Combination-specific human efficacy trials are lacking; both peptides remain research-use only.

Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.

Mechanism of action

The blend pairs two distinct mechanisms: CJC-1295 agonizes the GHRH receptor while ipamorelin agonizes the growth-hormone secretagogue (ghrelin) receptor. Because GHRH analogs and GHRPs act on separate pituitary pathways, their combined administration is studied for potentially synergistic, greater-than-additive GH release. Ipamorelin's selectivity is intended to add GH stimulation without notably raising cortisol or prolactin.

Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.

What it's studied for

Research contexts in which CJC-1295 + Ipamorelin Blend appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.

Key characteristics

A two-component blend, not a single peptide — hence no single sequence or molecular weight
Combines GHRH-receptor (CJC-1295) and ghrelin-receptor (ipamorelin) mechanisms
The dual-pathway rationale is potential synergy in GH release
Ipamorelin's selectivity aims to limit cortisol/prolactin effects
The CJC-1295 component may be the DAC or no-DAC form depending on the specific blend

Reported research dosing reference only

Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. CJC-1295 + Ipamorelin Blend is a research compound.

Blend dosing in the research literature mirrors the individual components: roughly 100-300 mcg of each peptide per reconstituted administration. These are reference figures for research context only, not dosing guidance for humans.

Common research-protocol reference: ~100-300 mcg of each component per dose
Body-weight-scaled reference for each: ~2 mcg/kg

Reported frequencyReported 1-3 times daily in research protocols, often fasted; frequency depends on whether the CJC-1295 component is DAC or no-DAC

ReconstitutionLyophilized combined vial; typically reconstituted with bacteriostatic water for research use

Effective duration depends on whether the CJC-1295 component includes DAC (multi-day) or is no-DAC (short-acting). Reference figures only, not human dosing guidance.

How it compares

Unlike single-agent GHRH analogs or GHRPs, this is a combination formulation designed to engage both the GHRH and ghrelin receptor pathways simultaneously.

Blend components

This entry documents a research-supplier blend combining the following. Each component is documented as its own PeptiDex entry where available:

CJC-1295Growth & GH-Axis IpamorelinGrowth & GH-Axis

Commonly studied alongside

Compounds frequently researched together with CJC-1295 + Ipamorelin Blend in the literature. Cross-referenced for research context — not a usage or combination recommendation.

CJC-1295 (with DAC)The DAC GHRH analog is one of the two components studied in this blend.IpamorelinThe selective GHRP component of the blend, paired with the GHRH analog for synergy.CJC-1295 (no DAC)The short-acting GHRH form often used as the CJC-1295 component of these blends.

Compare and calculate

Side-by-side pages for the pairings the literature already documents for CJC-1295 + Ipamorelin Blend, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.

Handling & Stability

Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.

Avoid repeated freeze-thaw cycles
Verify supplier lot and Certificate of Analysis
Follow institutional lab-safety protocols

Analytical & COA Concepts

Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:

Category Context

CJC-1295 + Ipamorelin Blend sits in the Growth & GH-Axis area of the PeptiDex library.

Research Supplier Listing

Where researchers source CJC-1295 + Ipamorelin Blend

For researchers studying CJC-1295 + Ipamorelin Blend, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.

View research-supplier listing →

Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.

Frequently asked questions

What is the CJC-1295 / Ipamorelin blend?

This is a combination research preparation containing both CJC-1295 (a GHRH analog) and ipamorelin (a selective GHRP / ghrelin-receptor agonist) in a single vial. It formalizes the most widely referenced GH-secretagogue research pairing into one product.

Why are CJC-1295 and ipamorelin combined?

The two act on different receptors: CJC-1295 on the GHRH receptor and ipamorelin on the ghrelin receptor (GHS-R1a). Stimulating both pathways simultaneously produces a synergistic GH pulse larger than either compound alone, which is the rationale for the blend in research settings.

Does the blend use CJC-1295 with DAC or without DAC?

Blends vary by source. Many CJC-1295 + ipamorelin blends use the no-DAC (Mod GRF 1-29) form so that both components are short-acting and produce a clean pulsatile profile, but some use the DAC version for sustained GHRH tone. The specific form should be confirmed on the product's COA.

What ratio is typical in the blend?

Combined vials are commonly referenced at a roughly 1:1 or 2:1 ratio of the two peptides (for example, comparable microgram amounts of each per reconstituted dose), but exact composition varies by supplier and should be read from the label/COA.

Is this blend an approved drug?

No. Neither component is an approved medication in this form, and combination peptide blends are supplied strictly as research chemicals, not for human therapeutic use.

Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.

References

No indexed primary literature located for this compound as of 2026-07-28. PubMed was searched for work specific to CJC-1295 + Ipamorelin Blend and none was found.

PeptiDex states this plainly rather than citing a study of a different compound to fill the space — the same null-not-guessed rule the specification table follows. See the editorial policy.